Fatores prognósticos de resposta à quimioterapia em tumores avançados do colo uterino: o papel da neoangiogênese.

Kfouri, Cláudio Franco do Amaral; Lombardi, Welington; Romania, Maria Clara Ferreira Nonato; Puls, Matheus; Martins-Ferreira, Rodrigo Amaral; Lombardi, Luciana Borges; Andrade, Jurandyr Moreira de

doi:10.1590/0100-6991e-20192077

Cited by 4 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Out of total 36 cases, 16 cases (26.67%) were observed as a positive to VEGF and 20 cases (33.33%) showed negativity. It is similar to a study conducted by Kfouri et al [ 25 ] who noticed that 16 patients were positive for VEGF protein and 24 patients were considered negative due to low expression. However, other study reported higher rates of VEGF expression (66%), used previous published histoscore ≥200 for defining positivity of VEGF expression compared to our study [ 26 ].…”

Section: Discussionsupporting

confidence: 88%

Prevalence of Angiogenesis, Proliferation, and Apoptosis Markers of Cervical Cancer and Their Correlation with Clinicopathological Parameters

Ramesh

Chander

Chitra

et al. 2020

Journal of Oncology

View full text Add to dashboard Cite

The aim of the study is to investigate the expression of angiogenesis (VEGF and PDGF), angiogenesis inhibitor markers (angiostatin and endostatin), proliferation (Ki67), and apoptosis markers (p53 and p16) of cervical cancer in Indian population and to correlate them with the clinicopathological profile. It is a descriptive study of consecutive cases of cervical cancer from Saveetha Medical College and Hospital between January 2017 and December 2018. The expression of angiogenesis, angiogenesis inhibitor markers, Ki67, p53, and p16 in 60 cases of cervical sections were detected by the immunohistochemical method and analyzed with clinicopathological data. VEGF expression was positive in 16 cases (26.67%) and negative in 20 cases (33.33%). As of PDGF, 3 cases (3.33%) have shown positivity to PDGF and 33 cases have shown negativity. Angiostatin and endostatin expression was reported to be positive in 10 (16.67%) and 21 (35%) cases, respectively. Most of the cases 57 (95%) have shown both p16 and Ki67 positivity. Although p53 expression was positive in 48 cases (80%), the remaining 12 cases (20%) were p53-negative. The PDGF expression was significantly correlated to the stage of tumors. No statistically significant association was observed between angiogenesis inhibitor markers and clinicopathological parameters. A significant positive correlation was noticed between the Ki67 expression and stage of tumors.

show abstract

Section: Discussionsupporting

confidence: 88%

Prevalence of Angiogenesis, Proliferation, and Apoptosis Markers of Cervical Cancer and Their Correlation with Clinicopathological Parameters

Ramesh

Chander

Chitra

et al. 2020

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…However, the clinical features vary greatly among the populations studied, making it difficult to estimate the appropriate values. Additionally, numerous studies have explored whether abnormal expression of certain molecular markers is associated with tumor resistance to chemotherapy, such as VEGF, HIF-1a, EGFL7, and LDH [ 28 – 31 ]. These markers have been linked to hypoxia and angiogenesis in the tumor microenvironment and may be related to drug concentrations in neoangiogenesis regions.…”

Section: Discussionmentioning

confidence: 99%

Successful neoadjuvant chemotherapy plus sintilimab for locally advanced cervical cancer: case series and review of the literature

Liu,

Deng,

Guo

et al. 2023

Diagn Pathol

View full text Add to dashboard Cite

Background The locally advanced cervical cancer (LACC) of FIGO stage IB3-IIA2 is characterized by large local mass, poor prognosis and survival rate. Tumor response to neoadjuvant chemotherapy for LACC, utilized as a surrogate endpoint, is urgently needed to improve. Given that the antitumor immune response can be suppressed by programed death-1 axis, the treatment paradigm of neoadjuvant chemotherapy combined with immunotherapy has been explored as one of the prognostic treatments in a variety of solid carcinoma. So far, the application of sintilimab, a domestic immune checkpoint inhibitor, combined with neoadjuvant chemotherapy is still limited in LACC, especially in large lesions. Case description We present three postmenopausal women diagnosed with FIGO stage IB3-IIA2 cervical squamous cell carcinoma with lesions larger than 5 cm. Demographic, clinical, histopathological, laboratory and imaging data were record. At the completion of the neoadjuvant therapy with paclitaxel plus carboplatin combined with sintilimab, all patients underwent hysterectomy. After neoadjuvant treatment, a pathologic complete response in case 1 and partial responses in case 2 and case 3 were achieved, and neither patient showed any relapse during the follow-up period of 16 to 22 months. Conclusions This report provide evidence to support the combination of sintilimab with neoadjuvant chemotherapy in cervical cancer, which has yet to be validated in prospective studies. More clinical data are needed to verify the effectiveness of the combined regimens. This literature review also collected studies involving potential predictors of response to NACT and immunotherapy, which would be helpful in stratifying patients for future trials.

show abstract

“…New pharmacological options, including drugs oriented toward repairing damaged DNA, such as poly(ADP-ribose) polymerase inhibitors, antiangiogenesis medications, and immune checkpoint inhibitors, have been developed over the past years in order to improve the prognosis of women with advanced CC [84,85]. Several clinical trials are in progress, such as those that have been testing pembrolizumab, a programmed death inhibitor (PD-1) that was recently approved by the Food and Drug Administration to treat advanced or recurrent CC.…”

Section: Discussionmentioning

confidence: 99%

Inequalities in Temporal Effects on Cervical Cancer Mortality in States in Different Geographic Regions of Brazil: An Ecological Study

Meira¹,

Magnago²,

Mendonça³

et al. 2022

Preprint

View full text Add to dashboard Cite

Cervical cancer is a public health issue with high disease burden and mortality in Brazil. The objectives of the present study were analyzing age, period, and cohort effects on cervical cancer mortality in women 20 years old or older from 1980 to 2019 in the North, South, and Southeast Regions of Brazil; and evaluating whether the implementation of a national screening program and the expansion of access to public health services caused impacts over the examined period and reduced the risk of death over the past years and among younger cohorts. The effects were estimated by applying Poisson regression models with estimable functions. The highest mortality rate by 100,000 women was found in Amazonas (24.13), and the lowest in São Paulo (10.56). A positive gradient was obtained for death rates as women’s age increased. The states in the most developed regions (South and Southeast) showed a reduction in the risk of death in the period that followed the implementation of the screening program and in cohort from the 1960s onwards. The North Region showed a decreased risk of death only in Amapá (2000–2004) and Tocantins (1995–2004; 2010–2019). The findings indicated that health inequities remain in Brazil and suggested that the health system has limitations regarding decreasing mortality associated with this type of cancer in regions with lower socioeconomic development.

show abstract

Fatores prognósticos de resposta à quimioterapia em tumores avançados do colo uterino: o papel da neoangiogênese.

Cited by 4 publications

References 20 publications

Prevalence of Angiogenesis, Proliferation, and Apoptosis Markers of Cervical Cancer and Their Correlation with Clinicopathological Parameters

Prevalence of Angiogenesis, Proliferation, and Apoptosis Markers of Cervical Cancer and Their Correlation with Clinicopathological Parameters

Successful neoadjuvant chemotherapy plus sintilimab for locally advanced cervical cancer: case series and review of the literature

Inequalities in Temporal Effects on Cervical Cancer Mortality in States in Different Geographic Regions of Brazil: An Ecological Study

Contact Info

Product

Resources

About